title: An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
authors.affiliation: Department of Hematology, Ebina General Hospital, Ebina, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ohgiya
authors.forename: Takahide
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suyama
authors.forename: Shigeki
authors.initials: S
authors.lastname: Watanabe
authors.forename: Hiroki
authors.initials: H
authors.lastname: Numata
authors.forename: Kosuke
authors.initials: K
authors.lastname: Tsuboi
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Sasao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001132:Arm; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D006801:Humans; D015994:Incidence; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib